Table 1.
Pre-vaccination characteristics of the study population: men vaccinated with at least two doses of SARS-CoV-2 mRNA vaccine without a previous exposure to the SARS-CoV-2 virus
| Number of men | 58 |
| Age (years) pre vaccination | 38.0 ± 6.1 (38.0) |
| Smoker | 3/58 (5.2%) |
| Father to children | 10/58 (17.2%) |
| Chronic disease or medication taken | 4/58 (%) |
| Testicular trauma or infection | 2/58 (3.4%) |
| Varicocele | 8/58 (13.8%) |
| Testicular (varicocele/hydrocele/undescended testicle) or inguinal hernia surgeries | 7/58 (12.1%) |
| Third vaccination given | 47/58 (81.0%) |
| Testosterone levels (mIU/ml)a | 16.3 ± 13.8 (15.1) |
| FSH levelsa (mIU/ml) a | 5.7 ± 2.9 (4.3) |
| LH levelsa (mIU/ml)a | 4.2 ± 1.5 (2.9) |
| Infertility diagnosis | |
| Male factor infertility | 16/58 (27.6%) |
| Ovulation disorder | 2/58 (3.4%) |
| Endometriosis | 4/58 (6.9%) |
| Ovarian insufficiency/ age related infertility | 11/58 (19.0%) |
| PGT | 6/58 (10.3%) |
| RPL | 2/58 (3.5%) |
| Female fertility preservation | 2/58 (3.5%) |
| Mechanical factor | 3/58 (5.2%) |
| Unexplained infertility | 12/58 (20.7%) |
| Days from first vaccination to semen analysis | 319.0 ± 61.4 (317.5) |
| Months from first vaccination to semen analysis | |
| 6–9 months | 13/58 (22.4%) |
| 9–14 months | 45 (77.6%) |
Data presented as n/N(%) or mean ± SD (median)
FSH, follicular stimulating hormone; LH, luteinizing hormone; PGT, preimplantation genetic testing; RPL, recurrent pregnancy loss
aHormonal profile pre-vaccination was available for 18 patients